Article

Attenuation of Cytotoxic Natural Product DNA Intercalating Agents by Caffeine

Department of Chemistry, University of Alabama in Huntsville, Huntsville, Alabama 35899, USA.
Scientia Pharmaceutica 09/2011; 79(4):729-47. DOI: 10.3797/scipharm.1107-19
Source: PubMed

ABSTRACT Many anti-tumor drugs function by intercalating into DNA. The xanthine alkaloid caffeine can also intercalate into DNA as well as form π-π molecular complexes with other planar alkaloids and anti-tumor drugs. The presence of caffeine could interfere with the intercalating anti-tumor drug by forming π-π molecular complexes with the drug, thereby blocking the planar aromatic drugs from intercalating into the DNA and ultimately lowering the toxicity of the drug to the cancer cells. The cytotoxic activities of several known DNA intercalators (berberine, camptothecin, chelerythrine, doxorubicin, ellipticine, and sanguinarine) on MCF-7 breast cancer cells, both with and without caffeine present (200 μg/mL) were determined. Significant attenuation of the cytotoxicities by caffeine was found. Computational molecular modeling studies involving the intercalating anti-tumor drugs with caffeine were also carried out using density functional theory (DFT) and the recently developed M06 functional. Relatively strong π-π interaction energies between caffeine and the intercalators were found, suggesting an "interceptor" role of caffeine protecting the DNA from intercalation.

Download full-text

Full-text

Available from: William N Setzer, Aug 14, 2014
4 Followers
 · 
187 Views
  • Source
    • "This mechanism of protection is known as " interceptor " mode of CAF and other methylxanthines action and was proposed by Bedner et al. [19]. The " interceptor " mode of CAF was described and analyzed for HCAs [15] and several other aromatic compounds: ethidium bromide [20] [21], propidium iodide [19] [20], quinacrine mustard, ICR170, ICR191 [22], proflavine [23], and several anticancer drugs [17] [24] [25]. Similar mechanism was also described for interaction of chlorophyllin (CHL) [26] and other natural constituents of human diet [27] with several aromatic compounds. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Food-borne heterocyclic aromatic amines (HCAs) are known mutagens and carcinogens present especially in Western population diet, which contains large amount of meat and its products. HCAs are capable of interacting with DNA directly through the formation of covalent adducts, however this process requires biological activation in liver, mainly by cytochrome P450 enzymes. This process may produce mutations and in consequence may contribute to the development of cancer. However, there are many studies showing that several biologically active aromatic compounds (BACs) may protect against genotoxic effects of HCAs. Direct interactions and noncovalent heterocomplexes formation may be one of the most important mechanisms of such protection. This work describes several BACs present in human diet, which are capable of molecular complexes formation with HCAs and protect cells as well as whole organisms against HCAs action.
    03/2013; vol. 2013, Article ID 740821. DOI:10.1155/2013/740821
  • Source
    • "At higher concentrations (>10 mM), caffeine potentiates the toxic effect [36]. To date, it is known that, on simultaneous addition or right after the main drug, CAF diminishes the toxicity of the antitumour antibiotics doxorubicin [30, 31, 33, 37–39], mitoxantrone [32] [33] [37] [39], ellipticine [33] [38], amsacrine [34], camptothecins [38] [40], and phenothiazine drugs [41] as well as the aromatic mutagen ethidium bromide [42] and aromatic neurotoxin tetrahydropyridine [43]. The " protector " effect has also been reported with respect to the aromatic mutagen quinacrine, ICR-191, ICR-170, IQ-type heterocyclic aromatic amines, and neocarzinostatin in the presence of caffeine and its derivatives [44] [45] [46] [47]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The mechanisms of synergistic biological effects observed in the simultaneous use of aromatic heterocyclic compounds in combination are reviewed, and the specific biological role of heteroassociation of aromatic molecules is discussed.
    Organic chemistry International 02/2013; 2013. DOI:10.1155/2013/278143
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer remains a fundamental burden to public health despite substantial efforts aimed at developing effective chemotherapeutics and significant advances in chemotherapeutic regimens. The major challenge in anti-cancer drug design is to selectively target cancer cells with high specificity. Research into treating malignancies by targeting altered metabolism in cancer cells is supported by computational approaches, which can take a leading role in identifying candidate targets for anti-cancer therapy as well as assist in the discovery and optimisation of anti-cancer agents. Natural products appear to have privileged structures for anti-cancer drug development and the bulk of this particularly valuable chemical space still remains to be explored. In this review we aim to provide a comprehensive overview of current strategies for computer-guided anti-cancer drug development. We start with a discussion of state-of-the art bioinformatics methods applied to the identification of novel anti-cancer targets, including machine learning techniques, the Connectivity Map and biological network analysis. This is followed by an extensive survey of molecular modelling and cheminformatics techniques employed to develop agents targeting proteins involved in the glycolytic, lipid, NAD+, mitochondrial (TCA cycle), amino acid and nucleic acid metabolism of cancer cells. A dedicated section highlights the most promising strategies to develop anti-cancer therapeutics from natural products and the role of metabolism and some of the many targets which are under investigation are reviewed. Recent success stories are reported for all the areas covered in this review. We conclude with a brief summary of the most interesting strategies identified and with an outlook on future directions in anti-cancer drug development.
    Current pharmaceutical design 09/2012; 19(4). DOI:10.2174/13816128130402 · 3.29 Impact Factor
Show more